AB1042 Dynamic contrast-enhanced magnetic resonance imaging in a randomized placebo-controlled rheumatoid arthritis trial – impact of applying joint coverage quality criteria
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1946
Abstract: Background Dynamic contrast-enhanced MRI (DCE-MRI) has been proposed for evaluating treatment response in RA. In a 16-week anti-TNF trial, DCE-MRI measures of inflammation analyzed for regions of interest (ROIs) covering MCP joints 2–5 and PIP… read more here.
Keywords: week; czp pbo; quality criteria; czp czp ... See more keywords
FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.2467
Abstract: Background Women with active chronic rheumatic inflammatory conditions (RA, PsA, AxSpA) often face uncertainty regarding the safety of the use of biologics during breastfeeding.1 Limited and non-validated data exist on the potential transfer of anti-TNFs… read more here.
Keywords: czp; ucb pharma; breast milk; pharma ... See more keywords
FRI0199 Systematic review and meta-analysis on certolizumab pegol for rheumatoid arthritis in adults
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.6433
Abstract: Background The appearance of tumor necrosis factor-alpha (TNFalpha) inhibitors dramatically changed the prognosis of rheumatoid arthritis. Certolizumab pegol (CZP) is a human Fab fragment of anti-TNFalpha monoclonal antibody which is approved for the treatment of… read more here.
Keywords: czp; arthritis; rheumatoid arthritis; meta analysis ... See more keywords
THU0224 Renacer study: efficacy and safety assessment of czp therapy in the treatment of 501 patients with rheumatoid arthritis(RA) among spanish population in clinical practice
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1186
Abstract: Background Certolizumab PEGol (CZP) differs from other anti-TNFs in that it is monovalent and it lacks the Fc region found in monoclonal antibodies. CZP is also PEGylated. Its efficacy in patients with rheumatoid arthritis (RA)… read more here.
Keywords: treatment; safety; study; efficacy ... See more keywords
SAT0274 Retention rates of certolizumab pegol in ankylosing spondylitis and non-radiographic axial spondyloarthritis patients: hur-bio real life results
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.4649
Abstract: Background Drug survival rate is generally accepted as a reliable indicator of both efficacy and safety profile of a biological DMARD. Objectives To evaluate survival rates of certolizumab-pegol (CZP) in ankylosing spondylitis (AS) and non-radiographic… read more here.
Keywords: certolizumab pegol; hur bio; nraxspa patients; rates certolizumab ... See more keywords
THU0114 CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2069
Abstract: Background: The presence of rheumatoid factor (RF) in patients (pts) with rheumatoid arthritis (RA) is associated with higher disease activity,1 and is regarded as a risk factor for more aggressive RA.1 Most studies on anti-tumour… read more here.
Keywords: ltd; efficacy; factor; pharma ... See more keywords
POS0022 PHARMACOVIGILANCE PREGNANCY DATA IN A LARGE POPULATION OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASE EXPOSED TO CERTOLIZUMAB PEGOL: PREGNANCY OUTCOMES AND CONFOUNDERS
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.577
Abstract: Background: Chronic inflammatory diseases (CID) in women of reproductive age are increasingly being treated with tumour necrosis factor inhibitors (TNFi), in line with recent guidelines.1 However, data on TNFi-exposed pregnancy outcomes are still limited. Certolizumab… read more here.
Keywords: pharmacovigilance; ucb pharma; pharma; pregnancy ... See more keywords
Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.808606
Abstract: Pegylation of biopharmaceuticals is the most common strategy to increase their half-life in the blood and is associated with a reduced immunogenicity. As antigen presentation is a primary event in the activation of CD4 T-cells… read more here.
Keywords: czp; certolizumab pegol; presentation cells; dendritic cells ... See more keywords
π-Bridge Effect on Symmetric Carbazole-Based Small Molecules for Realizing Ultraviolet Fluorescent Emission
Sign Up to like & getrecommendations! Published in 2018 at "Materials"
DOI: 10.3390/ma11040617
Abstract: A series of symmetric carbazole derivatives (CzP-H, CzP-CN, CzP-Me, and CzP-OMe), which comprise electron-donating and electron-drawing groups appending on a phenyl core, was synthesized and characterized in detail. These compounds exhibit excellent thermal stabilities, with… read more here.
Keywords: symmetric carbazole; czp czp; czp; czp ome ... See more keywords
Development of Lyophilised Eudragit® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15051554
Abstract: Clozapine (CZP) is the only effective drug in schizophrenia resistant to typical antipsychotics. However, existing dosage forms (oral or orodispersible tablets, suspensions or intramuscular injection) show challenging limitations. After oral administration, CZP has low bioavailability… read more here.
Keywords: administration; development lyophilised; czp; release ... See more keywords